As global markets react to the Federal Reserve's recent interest rate cut, small-cap stocks have shown a notable rally, reflecting their sensitivity to shifts in borrowing costs. In Asia, investors are closely watching how economic indicators and policy changes influence smaller companies, particularly as China's economy shows signs of slowing and Japan signals potential monetary policy normalization. In such a dynamic environment, identifying promising small-cap stocks often involves looking at those with strong fundamentals and active insider participation as potential indicators of confidence in future performance.

Name

PE

PS

Discount to Fair Value

Value Rating

Consun Pharmaceutical Group

12.8x

3.9x

39.71%

★★★★★☆

East West Banking

3.2x

0.8x

15.74%

★★★★☆☆

Cettire

NA

0.3x

26.80%

★★★★☆☆

BWP Trust

10.0x

13.1x

13.23%

★★★★☆☆

Hung Hing Printing Group

NA

0.4x

44.34%

★★★★☆☆

Daiwa House Logistics Trust

13.4x

7.0x

10.35%

★★★★☆☆

Southern Cross Electrical Engineering

17.1x

0.7x

30.15%

★★★☆☆☆

Gaush Meditech

12.1x

0.9x

0.71%

★★★☆☆☆

Pizu Group Holdings

13.7x

1.3x

34.69%

★★★☆☆☆

Far East Orchard

10.5x

3.4x

10.71%

★★★☆☆☆

Click here to see the full list of 42 stocks from our Undervalued Asian Small Caps With Insider Buying screener.

Here we highlight a subset of our preferred stocks from the screener.

Simply Wall St Value Rating: ★★★★★☆

Overview: HMC Capital is an investment management firm with operations in digital, real estate, private credit, and private equity sectors, and has a market cap of A$1.2 billion.

Operations: HMC Capital generates revenue primarily from its Digital, Real Estate, Private Credit, and Private Equity segments. The company has seen a notable trend in its gross profit margin reaching 100% consistently over recent periods. Operating expenses have been rising, with the most recent figure at A$138.9 million for the quarter ending September 2025. Net income margins have shown significant variability but recently achieved a high of 112.27% in December 2024 due to substantial non-operating gains offsetting operating expenses.

PE: 9.4x

HMC Capital, a smaller company in Asia's investment landscape, has drawn attention with insider confidence as Isaac Fried acquired 1 million shares for A$4.8 million. Recent earnings showed impressive growth with sales jumping to A$234.2 million from A$93.2 million and net income rising to A$147.3 million from A$66 million year-over-year, indicating potential value despite challenges like high-risk funding sources and strategic shifts in their renewable energy assets portfolio.

Navigate through the intricacies of HMC Capital with our comprehensive valuation report here.

Gain insights into HMC Capital's past trends and performance with our Past report.

Simply Wall St Value Rating: ★★★★★☆

Overview: Consun Pharmaceutical Group is a healthcare company engaged in the manufacture and sale of pharmaceuticals, with a market cap of CN¥5.23 billion.

Operations: The company's primary revenue streams come from the Consun Pharmaceutical Segment, contributing CN¥2.82 billion, and the Yulin Pharmaceutical Segment with CN¥469.22 million. The gross profit margin shows a notable trend, peaking at 80.68% in December 2015 before gradually declining to 74.19% by December 2024, with a slight recovery to 76.62% in June 2025. Operating expenses are primarily driven by sales and marketing costs, which reached CN¥1.09 billion by June 2025.

PE: 12.8x

Consun Pharmaceutical Group showcases its potential as an undervalued player in Asia's investment landscape. Recent insider confidence is evident with Meng An acquiring 251,000 shares, reflecting a transaction value of HK$2.85 million. The company reported half-year sales of CNY 1,568.59 million and net income of CNY 498.3 million, both up from the previous year. A recent dividend increase to HK$0.33 per share and completion of a buyback program further highlight its strategic financial maneuvers amidst growing earnings forecasts at 12.5% annually.

Dive into the specifics of Consun Pharmaceutical Group here with our thorough valuation report.

Understand Consun Pharmaceutical Group's track record by examining our Past report.

Simply Wall St Value Rating: ★★★☆☆☆

Overview: YSB operates in the wholesale distribution of pharmaceutical drugs, with a focus on providing a wide range of medical products to various healthcare institutions, and has a market capitalization of CN¥3.45 billion.

Operations: The company generates revenue primarily through its wholesale drug segment, with a recent revenue figure of CN¥18.93 billion. Over the periods observed, the gross profit margin showed an upward trend, reaching 10.76% by mid-2025. Operating expenses are significant and include substantial allocations to sales and marketing as well as general and administrative expenses. The net income has transitioned from negative figures to positive in 2024, indicating an improvement in profitability measures over time.

PE: 62.8x

YSB Inc. has shown promising growth, with net income for the first half of 2025 rising to CNY 78.12 million from CNY 21.82 million a year prior, driven by strong demand for its high-margin products and enhanced digital capabilities. The company repurchased 5,635,000 shares between May and June 2025 for HK$44.3 million, reflecting strategic capital management. Insider confidence is evident as Fei Chen acquired 300,000 shares worth approximately HK$1.9 million in recent months, signaling potential value recognition within the company’s leadership ranks despite reliance on external borrowing for funding needs.

Click here and access our complete valuation analysis report to understand the dynamics of YSB.

Evaluate YSB's historical performance by accessing our past performance report.

Unlock our comprehensive list of 42 Undervalued Asian Small Caps With Insider Buying by clicking here.

Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.

Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:HMC SEHK:1681 and SEHK:9885.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com